News & Updates
Filter by Specialty:
Muscle mass influences paclitaxel systemic exposure, informs personalized dosing
Extending the infusion duration of paclitaxel in breast cancer patients with low skeletal muscle area is expected to reduce peripheral neuropathy while maintaining systemic exposure, suggests a study.
Muscle mass influences paclitaxel systemic exposure, informs personalized dosing
29 Jun 2022
Netarsudil use for glaucoma may cause punctal stenosis
Use of topical netarsudil 0.02% for the treatment of glaucoma results in the development of reversible punctal stenosis, a recent study has found. This inflammation-mediated stenosis can cause tearing and related symptoms and may lead to treatment discontinuation with sufficient severity.
Netarsudil use for glaucoma may cause punctal stenosis
28 Jun 2022
Updated ASCEMBL results boost asciminib potential for CML
In the week-96 analysis of the phase III ASCEMBL trial, the first BCR::ABL1 STAMP* inhibitor asciminib sustained superiority over bosutinib for individuals with CML-CP** who have failed ≥2 lines of prior tyrosine kinase inhibitors (TKIs).
Updated ASCEMBL results boost asciminib potential for CML
28 Jun 2022
Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
Adolescents and adults with severe uncontrolled asthma while on inhaled corticosteroids (ICS) had greater responses to the human monoclonal antibody tezepelumab than placebo, according to prespecified exploratory results of the phase III NAVIGATOR trial.